Who
Hoyoung Huh
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Akari Therapeutics; Director, Pliant Therapeutics; Director and 10% owner, Peak Bio; Director, Eidos Therapeutics; Director, CytomX Therapeutics; Executive Chairman, Geron; Chairman, Scientific Adv. Bd., Rezolute; Director, Facet Biotech.
In numbers
- Trades disclosed
- 112
- Buys
- 14
- Sells
- 0
- Bought
- $24K
- Sold
- $0
- Companies
- 9
- Companies where not an officer
- 6
- First trade
- 6 Jun 2007
- Last trade
- 5 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $49K6,160 at $7.90 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $136K17,249 at $7.90 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —618,658 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $247K618,658 at $0.40 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —3,093,293 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $1.2M3,093,293 at $0.40 | filing |
| 5 Jun 2025filed 9 Jun 2025 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 20 Mar 2025filed 24 Mar 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 20 Mar 2025filed 24 Mar 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 6 Mar 2025filed 10 Mar 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $1000K892,857 at $1.12 | filing |
| 6 Mar 2025filed 10 Mar 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $1000K892,857 at $1.12 | filing |
| 6 Mar 2025filed 10 Mar 2025 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $1000K892,857 at $1.12 | filing |
| 14 Nov 2024filed 18 Nov 2024 | Peak Biooption or derivative | SEC FORM 4 Code C | —176,292 | filing |
| 14 Nov 2024filed 18 Nov 2024 | Peak Biooption or derivative | SEC FORM 4 Code D | —1,200,000 | filing |
| 14 Nov 2024filed 18 Nov 2024 | Peak Biooption or derivative | SEC FORM 4 Code D | — | filing |
| 14 Nov 2024filed 18 Nov 2024 | Peak Bio | SEC FORM 4 Code C | —4,574,661 | filing |
News
No headline names them, or the companies they trade most, lately.